OLD Second National Bank of Aurora Has $2.34 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

OLD Second National Bank of Aurora reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,829 shares of the company’s stock after selling 287 shares during the period. OLD Second National Bank of Aurora’s holdings in Zoetis were worth $2,335,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC grew its holdings in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the last quarter. VitalStone Financial LLC purchased a new position in Zoetis during the first quarter worth about $37,000. Evermay Wealth Management LLC boosted its holdings in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Finally, Worth Asset Management LLC purchased a new position in Zoetis during the first quarter worth about $26,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS traded up $1.33 during mid-day trading on Thursday, hitting $152.84. 1,304,234 shares of the stock traded hands, compared to its average volume of 2,941,219. The business’s 50-day moving average price is $177.35 and its 200 day moving average price is $180.39. The company has a market cap of $69.90 billion, a PE ratio of 30.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a 12-month low of $148.48 and a 12-month high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same period in the prior year, the firm posted $1.15 EPS. Zoetis’s revenue was up 8.5% on a year-over-year basis. On average, analysts expect that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. Zoetis’s dividend payout ratio is presently 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.12% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday. Stifel Nicolaus lowered their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. The Goldman Sachs Group lifted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Barclays boosted their price target on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.